DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia

Core Viewpoint - DiaMedica Therapeutics has received a No Objection Letter from Health Canada to initiate a Phase 2 clinical trial of DM199 for early-onset preeclampsia, marking a significant regulatory milestone for the company [1]. Group 1: Regulatory Approval and Clinical Trials - The No Objection Letter allows DiaMedica to start its Phase 2 study of DM199 in early-onset preeclampsia, with plans to expand into the United States and United Kingdom as further regulatory approvals are obtained [1]. - The Phase 2 trial will be an open-label, dose-ranging study evaluating DM199 in pregnant women diagnosed with early-onset preeclampsia between 24 and 32 weeks of gestation [1]. - The study aims to assess safety, tolerability, and exploratory efficacy markers, including changes in uterine artery pulsatility index and other preeclampsia-related biomarkers [1]. Group 2: Product Information - DM199 is a recombinant form of the human tissue kallikrein-1 protein, currently in clinical development for preeclampsia, fetal growth restriction, and acute ischemic stroke [1]. - The mechanism of DM199 is believed to improve arterial health, reduce blood pressure, and enhance microcirculatory blood flow, which are critical in managing preeclampsia [1]. Group 3: Company Overview - DiaMedica Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel treatments for serious ischemic diseases, including preeclampsia and acute ischemic stroke [1]. - The company’s lead candidate, DM199, is the first pharmaceutically active recombinant form of the KLK1 protein, which has established therapeutic applications in Asia [1].